Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 3/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25568152 | 1.00 | TDP1 (0.36) | TDP1KMT2AMEN1MAPK1EPHX1 | |
| SCHEMBL25568162 | 1.00 | TDP1 (0.36) | TDP1KMT2AMEN1MAPK1EPHX1 | |
| SCHEMBL3369497 | 0.88 | TDP1 (0.42) | TDP1KMT2AMEN1MAPK1EPHX1 | |
| SCHEMBL25568157 | 0.86 | DPP4 (0.35) | KMT2AMEN1MAPK1EPHX1ALDH1A1 | |
| SCHEMBL25568150 | 0.86 | DPP4 (0.35) | KMT2AMEN1MAPK1EPHX1ALDH1A1 | |
| SCHEMBL13877007 | 0.84 | TDP1 (0.40) | TDP1KMT2AMEN1MAPK1EPHX1 | |
| SCHEMBL7639921 | 0.83 | P2RX7 (0.42) | TDP1KMT2AMEN1MAPK1EPHX1 | |
| SCHEMBL23136344 | 0.83 | EPHX1 (0.35) | TDP1KMT2AMEN1MAPK1EPHX1 | |
| SCHEMBL25571678 | 0.82 | TDP1 (0.33) | TDP1KMT2AMEN1MAPK1EPHX1 | |
| SCHEMBL25571639 | 0.82 | TDP1 (0.33) | TDP1KMT2AMEN1MAPK1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TCOF1, SLC10A2, PAM | TDP1 3270/4885KMT2A 2833/4885MEN1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.